The Role of CBFb-MYH11 in Acute Myeloid Leukemia
CBFb-MYH11 在急性髓系白血病中的作用
基本信息
- 批准号:7367798
- 负责人:
- 金额:$ 37.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-04-15 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:AML1-ETO fusion proteinAccountingActivation AnalysisAcute Myelocytic LeukemiaAcute leukemiaAffectBehaviorBiochemicalBiological ModelsBlast CellBone Marrow EosinophiliaCBFp-MYH11CD34 geneCellsChimeric ProteinsChromosomes, Human, Pair 16Controlled EnvironmentCore-Binding FactorCritical PathwaysDiseaseElementsEnvironmentEquilibriumErinaceidaeFusion Protein ExpressionGene ExpressionGene Expression ProfileGene TargetingGenerationsGenesGeneticGoalsGrowthHematopoieticHumanIn VitroLeadMYH11 geneMitogen-Activated Protein KinasesModelingMutagenesisMutationNatureOncogenesOutcomePathway interactionsPatientsPre-studyPrincipal InvestigatorProtein FamilyProtein p53RoleSamplingSignal PathwaySignal TransductionStem cellsSystemTestingTreatment Protocolsfusion genegenetic elementhuman MYH11 proteinhuman diseasein vivoinsightknock-downleukemialeukemogenesisnotch proteinprotein functionself-renewalstemtherapeutic target
项目摘要
Translocations affecting a core binding factor (CBF) gene are one of the most frequent genetic aberrations in
human acute myeloid leukemia (AML), accounting for up to 25% of all AMLs. Nearly half of these are
associated with translocations affecting chromosome 16, resulting in expression of the fusion protein CBF[3-
MYH11. The overall objective of the proposed studies is to define the signaling pathways and downstream
target genes that are affected by CBF(3-MYH11,to evaluate the role of these regulated genes in leukemic
stem cell self-renewal, survival and differentiation,and to identify the signaling pathways that cooperate with
CBFP-MYH11 in leukemogenesis. To accomplish this goal, we propose to use the model of fusion gene
expression in human CD34+ cells we have developed, to study the pre-leukemia that is a result of CBFP-
MYH11 expression prior to the acquisition of cooperating mutations that lead to frank leukemia. We have
successfully used this system to model the related leukemia fusion protein AML1-ETO. The specific aims of
this proposal are as follows: Aim 1: Define the signaling pathways downstream of CBF(3-MYH11.
Expression of CBF(3-MYH11 in human CD34+ cells leads to their continued growth in vitro for an extended
period of greater than five months. These cells will be characterizedin terms of their proliferation, survival
and differentiation,and compared to the long-term cultures initiated by the related CBF fusion, AML1-ETO.
Aim 2: Identify target genes of CBFp-MYHl1 and analyze their role in CBFp-MYHl 1 -inducedproliferation.
A common gene expression profile will be identified by comparing the transcriptome of CD34+ cells from
our long-term cultures with normal CD34+ cells. We will analyze the contribution of these regulated target
genes by over-expressing those that are repressed, and conversely by knocking-down those genes that become
upregulated. Aim 3: Identify the signaling pathways that cooperate with CBFp-MYHl1 in leukemogenesis.
The pre-leukemic cultures expressing CBFp-MYHl1 will serve as the background in which cooperating
mutations will be tested. To identify specific signals that will cooperate in the transformation to acute
leukemia, defined eenetic elements and saturatine retroviral mutaeenesis will be used.
影响核心结合因子(CBF)基因的易位是最常见的遗传畸变之一,
人类急性髓细胞白血病(AML),占所有AML的25%。其中近一半是
与影响16号染色体的易位相关,导致融合蛋白CBF的表达[3-
MYH 11.拟议研究的总体目标是确定信号通路和下游
研究CBF(3-MYH 11)调控的靶基因,以评估这些调控基因在白血病发病中的作用。
干细胞自我更新,存活和分化,并确定与干细胞相互作用的信号通路。
CBFP-MYH 11在白血病发生中的作用为了实现这一目标,我们提出使用融合基因模型
我们已经开发了在人CD 34+细胞中的表达,以研究CBFP导致的白血病前期,
MYH 11在获得导致明显白血病的协同突变之前的表达。我们有
利用该系统成功构建了相关白血病融合蛋白AML 1-ETO。的具体目标
目的1:明确CBF(3-MYH 11)下游信号通路。
CBF β-MYH 11在人CD 34+细胞中的表达导致其在体外持续生长,
超过五个月的期限。这些细胞的特征是它们的增殖,存活
和分化,并与相关CBF融合AML 1-ETO启动的长期培养进行比较。
目的2:鉴定CBFp-MYH 11的靶基因,并分析其在CBFp-MYH 11诱导的细胞增殖中的作用。
将通过比较CD 34+细胞的转录组来鉴定共同的基因表达谱,
我们的长期培养与正常的CD 34+细胞。我们将分析这些调控目标的贡献
通过过度表达那些被抑制的基因,反过来通过敲低那些成为
上调。目的3:确定与CBFp-MYH 11在白血病发生中协同作用的信号通路。
表达CBFp-MYH 11的白血病前培养物将作为背景,在其中合作
突变将被测试。识别将在急性转化中合作的特定信号
白血病、确定的遗传元件和饱和逆转录病毒突变将被使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C MULLOY其他文献
JAMES C MULLOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C MULLOY', 18)}}的其他基金
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
9290731 - 财政年份:2017
- 资助金额:
$ 37.12万 - 项目类别:
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
MLL 融合蛋白在谱系确定和白血病发生中的指导作用
- 批准号:
10115634 - 财政年份:2017
- 资助金额:
$ 37.12万 - 项目类别:
Leukemia stem cell polarity and differentiation therapy
白血病干细胞极性与分化治疗
- 批准号:
10227111 - 财政年份:2017
- 资助金额:
$ 37.12万 - 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
- 批准号:
8618872 - 财政年份:2013
- 资助金额:
$ 37.12万 - 项目类别:
Genotype and phenotype of chemoresistant AML
化疗耐药性 AML 的基因型和表型
- 批准号:
8528938 - 财政年份:2013
- 资助金额:
$ 37.12万 - 项目类别:
The Role of MLL-AF9 in Acute Myeloid Leukemia
MLL-AF9 在急性髓系白血病中的作用
- 批准号:
7698026 - 财政年份:2009
- 资助金额:
$ 37.12万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 37.12万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 37.12万 - 项目类别: